Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Phase II study to test in first line the VAD (Vincristine Adriablastine Dexamethasone) + C
(Chlorambucil ) regimen associated to rituximab ( R-VAD + C ) in a cohort of young patients
under 66 years with a mantle cell lymphoma and also the test the role of an in vivo marrow
purge with rituximab before an autologous stem cell transplantation for the consolidation of
the patients which fulfilled a response to 4 cycles of (R VAD + C) regimen.